(Q39998237)

16 September 2017

title

Topical CpG enhances the response of murine malignant melanoma to dacarbazine (English)

1 reference

16 September 2017

Hossain M Najar

1

1 reference

16 September 2017

Jan P Dutz

series ordinal

2

1 reference

16 September 2017

language of work or name

English

0 references

publication date

27 March 2008

1 reference

Journal of Investigative Dermatology

16 September 2017

published in

1 reference

16 September 2017

volume

128

1 reference

16 September 2017

issue

9

1 reference

16 September 2017

page(s)

2204-2210

1 reference

https://scigraph.springernature.com/pub.10.1038/jid.2008.59

16 September 2017

exact match

0 references

cites work

Pathogen recognition and innate immunity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Medical management of melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Synergy between In situ Cryoablation and TLR9 Stimulation Results in a Highly Effective In vivo Dendritic Cell Vaccine

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Adoptive-cell-transfer therapy for the treatment of patients with cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Cross-presentation, dendritic cells, tolerance and immunity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

A Toll-like receptor recognizes bacterial DNA

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Immunotherapy of malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Development of TLR9 agonists for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Toll-Like Receptor Ligands Modulate Dendritic Cells to Augment Cytomegalovirus- and HIV-1-Specific T Cell Responses

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Mouse plasmacytoid cells: long-lived cells, heterogeneous in surface phenotype and function, that differentiate into CD8(+) dendritic cells only after microbial stimulus

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Identification and characterization of pDC-like cells in normal mouse skin and melanomas treated with imiquimod

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Mechanisms of hepatotoxicity caused by dacarbazine in rats

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

CpG-Oligodeoxynucleotides activate tyrosinase-related protein 2-specific T lymphocytes but do not lead to a protective tumor-specific memory response

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Apoptosis and melanoma chemoresistance

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

A novel dendritic cell subset involved in tumor immunosurveillance

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene: results from a murine tumour model

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.59

7 January 2021

Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD005413.PUB2

Identifiers

DOI

10.1038/JID.2008.59

1 reference

Dimensions Publication ID

16 September 2017

1028331861

0 references

1 reference